RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2008; 28(2): 152-167
DOI: 10.1055/s-2008-1062261
DOI: 10.1055/s-2008-1062261
Guillain-Barré Syndrome
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
19. März 2008 (online)
ABSTRACT
Guillain-Barré syndrome (GBS) is an acute-onset, monophasic, immune-mediated polyneuropathy that often follows an antecedent infection. The diagnosis relies heavily on the clinical impression obtained from the history and examination, although cerebrospinal fluid analysis and electrodiagnostic testing usually provide evidence supportive of the diagnosis. The clinician must also be familiar with mimics and variants to promptly and efficiently reach an accurate diagnosis. Intravenous immunoglobulin and plasma exchange are efficacious treatments. Supportive care during and following hospitalization is also crucial.
KEYWORDS
Guillain-Barré syndrome - inflammatory neuropathy - demyelinating neuropathy - acquired demyelinating neuropathy - Miller Fisher syndrome - acute inflammatory demyelinating polyradiculoneuropathy (AIDP) - acute motor axonal neuropathy
REFERENCES
- 1 Levin K H. Variants and mimics of Guillain Barré syndrome. Neurologist. 2004; 10 61-74
- 2 Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956; 255 57-65
- 3 Prineas J W. Pathology of the Guillain-Barré syndrome. Ann Neurol. 1981; 9(suppl) 6-19
- 4 Haymaker W E, Kernohan J W. The Landry-Guillain-Barré syndrome: clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore). 1949; 28 59-141
- 5 Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol. 1987; 22 753-761
- 6 Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré Syndrome Study Group. Neurology. 1985; 35 1096-1104
- 7 van der Meché F G, Schmitz P I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992; 326 1123-1129
- 8 Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997; 349 225-230
- 9 Chio A, Cocito D, Leone M et al.. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003; 60 1146-1150
- 10 Hughes R A, Rees J H. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997; 176(S2) S92-S98
- 11 Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol. 1990; 27(Suppl) S7-S12
- 12 Willison H J. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst. 2005; 10 94-112
- 13 Jacobs B C, Rothbarth P H, van der Meché F G et al.. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998; 51 1110-1115
- 14 Visser L H, van der Meché F G, Meulstee J et al.. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology. 1996; 47 668-673
- 15 Asbury A K, Cornblath D R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990; 27(suppl) S21-S24
- 16 Green D M, Ropper A H. Mild Guillain-Barré syndrome. Arch Neurol. 2001; 58 1098-1101
- 17 Winer J B, Hughes R A, Osmond C. A prospective study of acute idiopathic neuropathy. I. clinical features and their prognostic value. J Neurol Neurosurg Psychiatry. 1988; 51 605-612
- 18 Hughes R A, Cornblath D R. Guillain-Barré syndrome. Lancet. 2005; 366 1653-1666
- 19 Moulin D E, Hagen N, Feasby T E, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology. 1997; 48 328-331
- 20 Ravn H. The Landry-Guillain-Barré syndrome. A survey and a clinical report of 127 cases. Acta Neurol Scand. 1967; 43(suppl 30) 1-64
- 21 Ropper A H. The Guillain-Barré syndrome. N Engl J Med. 1992; 326 1130-1136
- 22 Asbury A K. Diagnostic considerations in Guillain-Barré syndrome. Ann Neurol. 1981; 9(Suppl) 1-5
- 23 Hughes R A, Wijdicks E F, Benson E et al.. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005; 62 1194-1198
- 24 Gracey D R, McMichan J C, Divertie M B, Howard Jr F M. Respiratory failure in Guillain-Barré syndrome: a 6-year experience. Mayo Clin Proc. 1982; 57 742-746
- 25 Lawn N D, Fletcher D D, Henderson R D, Wolter T D, Wijdicks E F. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001; 58 893-898
- 26 Massam M, Jones R S. Ventilatory failure in the Guillain-Barré syndrome. Thorax. 1980; 35 557-558
- 27 Newton-John H. Prevention of pulmonary complications in severe Guillain-Barré syndrome by early assisted ventilation. Med J Aust. 1985; 142 444-445
- 28 Chevrolet J C, Deleamont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré syndrome. Am Rev Respir Dis. 1991; 144 814-818
- 29 Ropper A H, Kehne S M. Guillain-Barré syndrome: management of respiratory failure. Neurology. 1985; 35 1662-1665
- 30 Flachenecker P, Hartung H P, Reiners K. Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study. Brain. 1997; 120(Pt 10) 1885-1894
- 31 Flachenecker P, Wermuth P, Hartung H P, Reiners K. Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol. 1997; 42 171-179
- 32 Lichtenfeld P. Autonomic dysfunction in the Guillain-Barré syndrome. Am J Med. 1971; 50 772-780
- 33 Zochodne D W. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve. 1994; 17 1145-1155
- 34 Truax B T. Autonomic disturbances in the Guillain-Barré syndrome. Semin Neurol. 1984; 4 462-468
- 35 Tuck R R, McLeod J G. Autonomic dysfunction in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1981; 44 983-990
- 36 Burns T M, Lawn N D, Low P A, Camilleri M, Wijdicks E F. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve. 2001; 24 963-965
- 37 Albers J W, Kelly Jr J J. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989; 12 435-451
- 38 Albers J W, Donofrio P D, McGonagle T K. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1985; 8 528-539
- 39 Ropper A H, Wijdicks E F, Shahani B T. Electrodiagnostic abnormalities in 113 consecutive patients with Guillain-Barré syndrome. Arch Neurol. 1990; 47 881-887
- 40 Gordon P H, Wilbourn A J. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol. 2001; 58 913-917
- 41 Cleland J C, Malik K, Thaisetthawatkul P, Herrmann D N, Logigian E L. Acute inflammatory demyelinating polyneuropathy: contribution of a dispersed distal compound muscle action potential to electrodiagnosis. Muscle Nerve. 2006; 33 771-777
- 42 Cornblath D R, Mellits E D, Griffin J W et al.. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol. 1988; 23 354-359
- 43 McKhann G M, Griffin J W, Cornblath D R, Mellits E D, Fisher R S, Quaskey S A. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988; 23 347-353
- 44 Crino P B, Zimmerman R, Laskowitz D, Raps E C, Rostami A M. Magnetic resonance imaging of the cauda equina in Guillain-Barré syndrome. Neurology. 1994; 44 1334-1336
- 45 Gorson K C, Ropper A H, Muriello M A, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996; 47 813-817
- 46 Weiss M D. Root enhancement in GBS. Neurology. 1997; 48 1477
- 47 Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol. 1992; 49 612-616
- 48 Oh S J, Kurokawa K, de Almeida D F, Ryan Jr H F, Claussen G C. Subacute inflammatory demyelinating polyneuropathy. Neurology. 2003; 61 1507-1512
- 49 Asbury A K, Arnason B G, Adams R D. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore). 1969; 48 173-215
- 50 Berciano J, Coria F, Monton F, Calleja J, Figols J, LaFarga M. Axonal form of Guillain-Barré syndrome: evidence for macrophage-associated demyelination. Muscle Nerve. 1993; 16 744-751
- 51 Feasby T E, Gilbert J J, Brown W F et al.. An acute axonal form of Guillain-Barré polyneuropathy. Brain. 1986; 109(Pt 6) 1115-1126
- 52 Feasby T E, Gilbert J J, Brown W F et al.. Acute “axonal” Guillain-Barré polyneuropathy. Neurology. 1987; 37 357
- 53 Feasby T E, Hahn A F, Brown W F, Bolton C F, Gilbert J J, Koopman W J. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms?. J Neurol Sci. 1993; 116 185-192
- 54 Ropper A H. Severe acute Guillain-Barré syndrome. Neurology. 1986; 36 429-432
- 55 Griffin J W, Li C Y, Ho T W et al.. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996; 39 17-28
- 56 Griffin J W, Li C Y, Macko C et al.. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996; 25 33-51
- 57 Sobue G, Li M, Terao S et al.. Axonal pathology in Japanese Guillain-Barré syndrome: a study of 15 autopsied cases. Neurology. 1997; 48 1694-1700
- 58 Hafer-Macko C, Hsieh S T, Li C Y et al.. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996; 40 635-644
- 59 McKhann G M, Cornblath D R, Griffin J W et al.. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993; 33 333-342
- 60 Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology. 2003; 61 471-474
- 61 Hiraga A, Mori M, Ogawara K et al.. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2005; 76 719-722
- 62 Overell J R, Willison H J. Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol. 2005; 18 562-566
- 63 Yuki N, Taki T, Takahashi M et al.. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol. 1994; 36 791-793
- 64 Ogawara K, Kuwabara S, Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve. 2002; 26 845-849
- 65 Chaudhry F, Gee K E, Vaphiades M S, Biller J, Jay W. GQ1b antibody testing in Guillain-Barré syndrome and variants. Semin Ophthalmol. 2006; 21 223-227
- 66 Radziwill A J, Steck A J, Borruat F X, Bogousslavsky J. Isolated internal ophthalmoplegia associated with IgG anti-GQ1b antibody. Neurology. 1998; 50 307
- 67 Odaka M, Yuki N, Yamada M et al.. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003; 126 2279-2290
- 68 Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992; 31 677-679
- 69 Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993; 43 1911-1917
- 70 Onodera M, Mori M, Koga M et al.. Acute isolated bulbar palsy with anti-GT1a IgG antibody subsequent to Campylobacter jejuni enteritis. J Neurol Sci. 2002; 205 83-84
- 71 Kashihara K, Shiro Y, Koga M, Yuki N. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1998; 65 799
- 72 Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci. 2004; 219 139-145
- 73 Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol. 2004; 148 200-205
- 74 Fross R D, Daube J R. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology. 1987; 37 1493-1498
- 75 Nagaoka U, Kato T, Kurita K et al.. Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome. Neurology. 1996; 47 1601-1602
- 76 Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001; 56 1104-1106
- 77 Willison H J. Ganglioside complexes as targets for antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 2006; 77 1002-1003
- 78 Schaublin G A, Michet Jr C J, Dyck P J, Burns T M. An update on the classification and treatment of vasculitic neuropathy. Lancet Neurol. 2005; 4 853-865
- 79 Mori K, Hattori N, Sugiura M et al.. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology. 2002; 58 979-982
- 80 Keesey J C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004; 29 484-505
- 81 Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998; 21 701-710
- 82 Li J, Loeb J A, Shy M E et al.. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol. 2003; 53 703-710
- 83 Jeha L E, Sila C A, Lederman R J, Prayson R A, Isada C M, Gordon S M. West Nile virus infection: a new acute paralytic illness. Neurology. 2003; 61 55-59
- 84 Halperin J J. Lyme disease and the peripheral nervous system. Muscle Nerve. 2003; 28 133-143
- 85 Steere A C. Lyme disease. N Engl J Med. 2001; 345 115-125
- 86 Donofrio P D, Wilbourn A J, Albers J W, Rogers L, Salanga V, Greenberg H S. Acute arsenic intoxication presenting as Guillain-Barré-like syndrome. Muscle Nerve. 1987; 10 114-120
- 87 Grattan-Smith P J, Morris J G, Johnston H M et al.. Clinical and neurophysiological features of tick paralysis. Brain. 1997; 120(Pt 11) 1975-1987
- 88 Vedanarayanan V V, Evans O B, Subramony S H. Tick paralysis in children: electrophysiology and possibility of misdiagnosis. Neurology. 2002; 59 1088-1090
- 89 Albers J W, Fink J K. Porphyric neuropathy. Muscle Nerve. 2004; 30 410-422
- 90 Calderon-Gonzalez R, Rizzi-Hernandez H. Buckthorn polyneuropathy. N Engl J Med. 1967; 277 69-71
- 91 Piradov M A, Pirogov V N, Popova L M, Avdunina I A. Diphtheritic polyneuropathy: clinical analysis of severe forms. Arch Neurol. 2001; 58 1438-1442
- 92 Snider W D, Simpson D M, Nielsen S, Gold J W, Metroka C E, Posner J B. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol. 1983; 14 403-418
- 93 Roullet E, Assuerus V, Gozlan J et al.. Cytomegalovirus multifocal neuropathy in AIDS: analysis of 15 consecutive cases. Neurology. 1994; 44 2174-2182
- 94 Hafer-Macko C E, Sheikh K A, Li C Y et al.. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996; 39 625-635
- 95 Ilyas A A, Willison H J, Quarles R H et al.. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol. 1988; 23 440-447
- 96 Oomes P G, Jacobs B C, Hazenberg M P, Bänffer J R, van der Meché F G. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol. 1995; 38 170-175
- 97 Sheikh K A, Nachamkin I, Ho T W et al.. Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: molecular mimicry and host susceptibility. Neurology. 1998; 51 371-378
- 98 Vriesendorp F J, Mishu B, Blaser M J, Koski C L. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol. 1993; 34 130-135
- 99 Willison H J. Ganglioside complexes: new autoantibody targets in Guillain-Barré syndromes. Nat Clin Pract Neurol. 2005; 1 2-3
- 100 Olsson Y. Topographical differences in the vascular permeability of the peripheral nervous system. Acta Neuropathol. 1968; 10 26-33
- 101 Ho T W, Mishu B, Li C Y et al.. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995; 118(Pt 3) 597-605
- 102 Yuki N, Taki T, Inagaki F et al.. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993; 178 1771-1775
- 103 Ho T W, Li C Y, Cornblath D R et al.. Patterns of recovery in the Guillain-Barré syndromes. Neurology. 1997; 48 695-700
- 104 Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997; 745 32-36
- 105 Bril V, Ilse W K, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996; 46 100-103
- 106 Donofrio P D. Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve. 2003; 28 273-292
- 107 Hughes R A, Wijdicks E F, Barohn R et al.. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003; 61 736-740
- 108 Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol. 1992; 32 94-97
- 109 McKhann G M, Griffin J W, Cornblath D R, Mellits E D, Fisher R S, Quaskey S A. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988; 23 347-353
- 110 McKhann G M, Griffin J W, Cornblath D R, Quaskey S A, Mellits E D. Role of therapeutic plasmapheresis in the acute Guillain-Barré syndrome. J Neuroimmunol. 1988; 20 297-300
- 111 The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome . Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997; 41 298-306
- 112 Abd-Allah S A, Jansen P W, Ashwal S, Perkin R M. Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome. J Child Neurol. 1997; 12 376-380
- 113 Jansen P W, Perkin R M, Ashwal S. Guillain-Barré syndrome in childhood: natural course and efficacy of plasmapheresis. Pediatr Neurol. 1993; 9 16-20
- 114 Jones H R. Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol. 1996; 11 4-12
- 115 Vallee L, Dulac O, Nuyts J P, Leclerc F, Vamecq J. Intravenous immune globulin is also an efficient therapy of acute Guillain-Barré syndrome in affected children. Neuropediatrics. 1993; 24 235-236
- 116 Epstein M A, Sladky J T. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol. 1990; 28 65-69
- 117 Raphaël J C, Chevret S, Hughes R A, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2001; (2) CD001798
- 118 Esperou H, Jars-Guincestre M C, Bolgert F, Raphael J C, Durand-Zaleski I. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Intensive Care Med. 2000; 26 1094-1100
- 119 Osterman P O, Fagius J, Lundemo G et al.. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984; 2 1296-1299
- 120 Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barré syndrome. Neurology. 1998; 51 875-877
- 121 Lehmann H C, Hartung H P, Hetzel G R, Stuve O, Kieseier B C. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol. 2006; 63 1066-1071
- 122 Dalakas M C. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004; 102 177-193
- 123 Dalakas M C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004; 291 2367-2375
- 124 Thornton C A, Ballow M. Safety of intravenous immunoglobulin. Arch Neurol. 1993; 50 135-136
- 125 Hughes R A, Newsom-Davis J M, Perkin G D, Pierce J M. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978; 2 750-753
- 126 Hughes R A, van Der Meché F G. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev. 2000; (3) CD001446
- 127 Hughes R A, Swan A V, van Koningsveld R, van Doorn P A. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2006; (2) CD001446
- 128 van Koningsveld R, Schmitz P I, Meché F G et al.. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004; 363 192-196
- 129 Okamiya S, Ogino M, Ogino Y et al.. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome. Ther Apher Dial. 2004; 8 248-253
- 130 Haupt W F, Rosenow F, van der Ven C, Birkmann C. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis. Ther Apher. 2000; 4 195-197
- 131 Haupt W F, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci. 1996; 137 145-149
- 132 Romano J G, Rotta F T, Potter P et al.. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve. 1998; 21 1327-1330
- 133 Visser L H, van der Meché F G, Meulstee J, van Doorn P A. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. J Neurol Neurosurg Psychiatry. 1998; 64 242-244
- 134 Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007; 68 1144-1146
- 135 Mori M, Kuwabara S, Fukutake T, Hattori T. Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. J Neurol Neurosurg Psychiatry. 2002; 72 680
- 136 Overell J R, Hsieh S, Odaka M, Yuki N, Willison H J. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007; 1 CD004761
- 137 Fletcher D D, Lawn N D, Wolter T D, Wijdicks E F. Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. Neurology. 2000; 54 2311-2315
- 138 Gold R, Bayas A, Toyka K V. Autoimmune neuropathies-current aspects of immunopathologic diagnostics and therapy. Nervenarzt. 2005; 76 1009-1021 quiz 1022-1023
- 139 Sunderrajan E V, Davenport J. The Guillain-Barré syndrome: pulmonary-neurologic correlations. Medicine (Baltimore). 1985; 64 333-341
- 140 Pontoppidan H, Geffin B, Lowenstein E. Acute respiratory failure in the adult. 2. N Engl J Med. 1972; 287 743-752
- 141 Lawn N D, Wijdicks E F. Post-intubation pulmonary function test in Guillain-Barré syndrome. Muscle Nerve. 2000; 23 613-616
- 142 Durand M C, Porcher R, Orlikowski D et al.. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol. 2006; 5 1021-1028
- 143 Sharshar T, Chevret S, Bourdain F, Raphael J C. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome . Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med. 2003; 31 278-283
- 144 Durand M C, Lofaso F, Lefaucheur J P et al.. Electrophysiology to predict mechanical ventilation in Guillain-Barré syndrome. Eur J Neurol. 2003; 10 39-44
- 145
Henderson R D, Lawn N D, Fletcher D D, McClelland R L, Wijdicks E F.
The morbidity of Guillain-Barré syndrome admitted to the intensive care unit.
Neurology.
2003;
60
17-21
MissingFormLabel
- 146 Holdgaard H O, Pedersen J, Jensen R H et al.. Percutaneous dilatational tracheostomy versus conventional surgical tracheostomy. A clinical randomised study. Acta Anaesthesiol Scand. 1998; 42 545-550
- 147 Emmons P R, Blume W T, DuShane J W. Cardiac monitoring and demand pacemaker in Guillain-Barré syndrome. Arch Neurol. 1975; 32 59-61
- 148 Favre H, Foex P, Guggisberg M. Use of demand pacemaker in a case of Guillain-Barré syndrome. Lancet. 1970; 1 1062-1063
- 149 Singh N K, Jaiswal A K, Misra S, Srivastava P K. Assessment of autonomic dysfunction in Guillain-Barré syndrome and its prognostic implications. Acta Neurol Scand. 1987; 75 101-105
- 150 McLeod J G. Invited review: autonomic dysfunction in peripheral nerve disease. Muscle Nerve. 1992; 15 3-13
- 151 Clarke E, Bayliss R IS, Cooper R. Landry-Guillain-Barré syndrome: cardiovascular complications; treatment with A.C.T.H. and cortisone. BMJ. 1954; 2(4903) 1504-1507
- 152 Kogan B A, Solomon M H, Diokno A C. Urinary retention secondary to Landry-Guillain-Barré syndrome. J Urol. 1981; 126 643-644
- 153 Samama M M, Cohen A T, Darmon J Y et al.. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med. 1999; 341 793-800
- 154 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988; 318 1162-1173
- 155 Clagett G P, Reisch J S. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988; 208 227-240
- 156 Pandey C K, Bose N, Garg G et al.. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002; 95 1719-1723
- 157 Tripathi M, Kaushik S. Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med. 2000; 28 655-658
- 158 Meythaler J M. Rehabilitation of Guillain-Barré syndrome. Arch Phys Med Rehabil. 1997; 78 872-879
- 159 Herbison G J, Jaweed M M, Ditunno Jr J F. Exercise therapies in peripheral neuropathies. Arch Phys Med Rehabil. 1983; 64 201-205
- 160 Pitetti K H, Barrett P J, Abbas D. Endurance exercise training in Guillain-Barré syndrome. Arch Phys Med Rehabil. 1993; 74 761-765
- 161 Cooke J F, Orb A. The recovery phase in Guillain-Barré syndrome: moving from dependency to independence. Rehabil Nurs. 2003; 28 105-108, 130
- 162 Bernsen R A, de Jager A E, Schmitz P I, van der Meché F G. Long-term impact on work and private life after Guillain-Barré syndrome. J Neurol Sci. 2002; 201 13-17
- 163 Bernsen R A, de Jager A E, van der Meché F G, Suurmeijer T P. How Guillain-Barré patients experience their functioning after 1 year. Acta Neurol Scand. 2005; 112 51-56
- 164 Rees J H, Thompson R D, Smeeton N C, Hughes R A. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998; 64 74-77
- 165 The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group. Brain. 1996; 119(Pt 6) 2053-2061
- 166 Bernsen R A, de Jager A E, Schmitz P I, van der Meché F G. Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology. 1999; 53 409-410
- 167 Prevots D R, Sutter R W. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis. 1997; 175(Sl) S151-S155
- 168 van Koningsveld R, Steyerberg E W, Hughes R A, Swan A V, van Doorn P A, Jacobs B C. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007; 6 589-594
- 169 Bradshaw D Y, Jones Jr H R. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve. 1992; 15 500-506
- 170 Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr. 2003; 142 305-309
- 171 de Jager A E, Minderhoud J M. Residual signs in severe Guillain-Barré syndrome: analysis of 57 patients. J Neurol Sci. 1991; 104 151-156
- 172 Garssen M P, Van Koningsveld R, Van Doorn P A. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome. J Neurol. 2006; 253 1143-1146
- 173 Merkies I S, Schmitz P I, Samijn J P, van der Meché F G, van Doorn P A. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 1999; 53 1648-1654
- 174 Garssen M P, van Doorn P A, Visser G H. Nerve conduction studies in relation to residual fatigue in Guillain-Barré syndrome. J Neurol. 2006; 253 851-856
- 175 Garssen M P, Schmitz P I, Merkies I S, Jacobs B C, van der Meché F G, van Doorn P A. Amantadine for treatment of fatigue in Guillain-Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry. 2006; 77 61-65
- 176 Garssen M P, Bussmann J B, Schmitz P I et al.. Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology. 2004; 63 2393-2395
- 177 Hughes R A, Charlton J, Latinovic R, Gulliford M C. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med. 2006; 166 1301-1304
- 178 Juurlink D N, Stukel T A, Kwong J et al.. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006; 166 2217-2221
- 179 Lasky T, Terracciano G J, Magder L et al.. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998; 339 1797-1802
- 180 Fenichel G M. Assessment: neurologic risk of immunization: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 1999; 52 1546-1552
- 181 Wijdicks E F, Fletcher D D, Lawn N D. Influenza vaccine and the risk of relapse of Guillain-Barré syndrome. Neurology. 2000; 55 452-453
- 182 Pritchard J, Mukherjee R, Hughes R A. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry. 2002; 73 348-349
Ted M BurnsM.D.
Department of Neurology, University of Virginia
PO Box 800394, Charlottesville, VA 22908
eMail: tmb8r@virginia.edu